SHR-1701 + gemcitabine + cisplatin

SHR-1701 + gemcitabine + cisplatin is a combination investigational regimen composed of three agents: - **SHR-1701**, a bifunctional fusion protein that targets both programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β). SHR-1701 acts as an immunotherapy by blocking immunosuppressive signaling through both PD-L1 and TGF-β pathways, enhancing antitumor immune responses in a variety of advanced solid tumors[1][3][5]. It is developed by Jiangsu Hengrui Pharmaceuticals. - **Gemcitabine**, a nucleoside analog antimetabolite that inhibits DNA synthesis and is used as a cytotoxic chemotherapeutic agent for multiple cancers, especially biliary, pancreatic, and lung cancer[2][4][6]. - **Cisplatin**, a platinum-based alkylating agent causing DNA crosslinking and apoptosis in cancer cells, also widely used in combination chemotherapy[2][4][6]. This triple combination aims to provide synergistic antitumor activity by combining immune checkpoint inhibition, TGF-β pathway blockade, and direct cytotoxicity. While SHR-1701 is under clinical evaluation, gemcitabine and cisplatin are established chemotherapeutic agents with synergistic, additive effects as a doublet in many cancers.